Mei Sheng Duh

Analysis Group (United States) — United States

Medicine · Health Sciences

51h-index11.7kcitations696works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(54), Economic and Financial Impacts of Cancer(49), Hemoglobinopathies and Related Disorders(46), Multiple Myeloma Research and Treatments(45), Chronic Lymphocytic Leukemia Research(44)

Publications696 total

Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study)
Kidney Medicine·2025Open Access
Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
UNC Libraries·2025Open Access
Improved overall survival in patients with advanced systemic mastocytosis treated with avapritinib versus real-world therapy based on mutation-adjusted risk score (MARS) stratification
Blood·2025
Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records data
Blood·2025Open Access
Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy
Journal of VitreoRetinal Diseases·2025· 1 cited
Real-world treatment patterns and clinical outcomes of patients with treatment-naïve and relapsed/refractory diffuse large B-cell lymphoma in the United States
Leukemia Research·2025
P3.12.06 Pralsetinib (Phase 1/2 ARROW Trial) Compared With Best Available Therapy (External Control) in Pretreated RET Fusion+ NSCLC
Journal of Thoracic Oncology·2025
#3452 Real-world effectiveness of ravulizumab in adults with aHUS who switched to ravulizumab within 3 months of eculizumab treatment (aHUS IMPACT)
Nephrology Dialysis Transplantation·2025Open Access
Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma
JCO oncology advances.·2025Open Access
Burden of eosinophilic granulomatosis with polyangiitis by disease phase and steroid-sparing effects of biologics: a real-world retrospective study in Europe
ERJ Open Research·2025Open Access
Association of hepatitis B surface antigen loss with clinical outcomes among patients with chronic hepatitis B infection: a retrospective cohort study in the United States
Zeitschrift für Gastroenterologie·2025
Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study
Leukemia Research·2025· 1 citedOpen Access
CO119 Bridging the Gap between the NAPOLI 3 Trial and Real-World Practice: Real-World Overall Survival (OS) of First-Line (1L) FOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Value in Health·2025
EE279 Economic Burden of Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP): A Large United States (US) Nationwide Claims Analysis
Value in Health·2025
P60 Antimicrobial resistance among female patients with uncomplicated urinary tract infections in England: a physician panel chart review
JAC-Antimicrobial Resistance·2025Open Access
Overall survival (OS) with NALIRIFOX (NFX) compared to FOLFIRINOX (FFX) in patients not previously treated for metastatic pancreatic ductal adenocarcinoma (mPDAC): An external control arm study.
Journal of Clinical Oncology·2025
Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes
Frontiers in Allergy·2025Open Access
Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma
Blood Advances·2025· 2 citedOpen Access
IP15-35 PATIENT CHARACTERISTICS AND RESISTANCE PHENOTYPES AMONG PATIENTS WITH COMPLICATED URINARY TRACT INFECTION CAUSED BY EXTENDED-SPECTRUM Β-LACTAMASE PRODUCING ENTEROBACTERALES: A US RETROSPECTIVE COHORT STUDY
The Journal of Urology·2025
Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data
Infection·2025· 1 citedOpen Access
page 1 of 35Next →

Frequent Co-authors

Patrick Lefèbvre(18), François Laliberté(9), Marie‐Hélène Lafeuille(8), Francis Vekeman(6), Edward Faught(4), Héctor Ortega(4), Pierre Emmanuel Paradis(4), Sujata P. Sarda(4), Andrine R. Swensen(3), Annie Guérin(3), Laurence Gozalo(3), Marie-Noëlle Robitaille(3), Frank C. Albers(3), Steve Yancey(3), Mark Forshag(3), Xiwu Lin(3), Anand A. Dalal(3), Alex Trahey(3), Caroline Korves(3), Jennifer Weiner(2)